Valo is using human-centric data and artificial intelligence-powered compute across the entire drug development lifecycle into a single unified architecture, with the aim to accelerate and transform the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate.
Valo's Opal Computational Platform™, a fully integrated, closed loop, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.
